Photo from Akash Maniam/LinkedIn
Sep 16, 2024, 11:39
Akash Maniam: Brilliantly designed I-SPY2 trial
Akash Maniam, shared on LinekdIn:
“Brilliantly designed I-SPY2 trial – adaptive neoadjuvant treatments for early breast cancer, stratified by receptor status, DNA repair deficiency and immunogenicity and tailored according to predicted response.
The ADC/IO synergy continues to grow and this trial could really set the platform for personalised de-escalation and intensification approaches.
Great abstract at ESMO24.”
Source: Akash Maniam/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19